Evaluation of first-trimester tricuspid regurgitation for Down syndrome screening.
Screening for Down syndrome has become an integral part of prenatal care. In recent years, there has been significant interest in first-trimester screening methods. Increased nuchal translucency in the first trimester of pregnancy has been identified as a marker for chromosomal anomalies and congenital cardiac disease. In addition, research has identified a correlation between tricuspid regurgitation, diagnosed by pulsed-wave Doppler ultrasonography, in aneuploid fetuses between 11 and 13 + 6 weeks' gestation. This article provides a brief historical overview of screening for aneuploidy and examines the emerging trend and pitfalls of first-trimester screening.
McGee
Deborah Cooper
DC
Obstetrix Medical Group of Colorado, Perinatal Nurse Practitioner Services, Presbyterian/St. Luke's Medical Center, Denver, CO 80218, USA. deborah_mcgee@pediatrix.com
D004314:Down Syndrome / Q000150:complications / Q000000981:diagnostic imaging* / Q000235:genetics; D005069:Evaluation Studies as Topic; D005260:Female; D005865:Gestational Age; D006801:Humans; D008403:Mass Screening / Q000379:methods* / Q000451:nursing / Q000639:trends; D009030:Mosaicism; D048208:Nuchal Translucency Measurement; D024802:Nurse's Role; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D015203:Reproducibility of Results; D018570:Risk Assessment; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014178:Translocation, Genetic / Q000235:genetics; D014262:Tricuspid Valve Insufficiency / Q000150:complications / Q000000981:diagnostic imaging* / Q000235:genetics; D018617:Ultrasonography, Doppler, Pulsed; D016216:Ultrasonography, Prenatal / Q000379:methods* / Q000451:nursing / Q000639:trends